Mie University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 4
Founded: Tsu Japan (1949)

Organization Overview

First Clinical Trial
2005
NCT00291473
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Department of Immuno-Gene Therapy, Mie University, graduate School of Medicine | Department of Immuno-Gene Therapy, Mie University, Graduate School of Medicine Mie University Hospital | Mie University | Mie University Hospital

Active Ingredients

Drugs in Phase 4 Trials (1)

cilostazol (pletal) (1 trial)

Drugs in Phase 2 Trials (1)

bromocriptine (parlodel) (1 trial)

Drugs in Phase 1 Trials (3)

chp-her2, chp-ny-eso-1 (1 trial)

tbi-1201 (1 trial)

tbi-1301 (1 trial)

Drugs in Other Trials (1)

ranibizumab (lucentis) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Stomach Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial APIs: 6